RxDoctor Payments DataLook up a doctor →

James Harvey, MD

Interventional Cardiology · Chambersburg, PANPI 1417969536

Payments from drug & device makers

$1,027,698in general payments, 2019–2025

Across 783 payments — averaging $1312.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$411K
  • Boston Scientific$354K
  • Edwards Lifesciences$154K
  • Bard Peripheral Vascular, Inc.$35K
  • Baylis Medical Company Inc$31K
  • Abiomed$29K
  • plus $15K from 28 others
$35,906in research payments, 2019–2025

Across 25 payments — averaging $1436.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$36K

What the payments were for

  • Consulting fees$73,75017%
  • Speaking & faculty fees$294,06967%
  • Travel & lodging$58,75013%
  • Food & beverage$15,2123%
  • Education$210%
  • Entertainment$2240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027,698 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$99,183
Medicare patients
145
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate24$291
Ezetimibe12$228

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →